Sotera Health (SHC) Financials

$15.43 -0.35 (-2.22%)

Closing price 04:00 PM Eastern

Extended Trading

$15.25 -0.18 (-1.17%)

As of 05:04 PM Eastern

Annual Income Statements for Sotera Health

This table shows Sotera Health's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Net Income / (Loss) Attributable to Common Shareholders	-21	-39	117	-375	51	44	78
Consolidated Net Income / (Loss)	-20	-37	117	-375	51	44	78
Net Income / (Loss) Continuing Operations	-20	-37	117	-375	51	44	78
Total Pre-Tax Income	-0.92	-39	176	-243	106	114	148
Total Operating Income	184	206	257	248	277	298	362
Total Gross Profit	395	444	519	557	577	602	646
Total Revenue	778	818	931	0.00	1,049	1,100	1,164
Operating Revenue	778	818	931	-	1,049	1,100	1,164
Total Cost of Revenue	383	375	413	447	472	498	518
Operating Cost of Revenue	383	375	413	56	472	498	518
Total Operating Expenses	212	238	262	246	300	305	284
Selling, General & Admin Expense	147	179	198	246	237	243	253
Amortization Expense	59	59	64	-	64	62	31
Total Other Income / (Expense), net	-185	-245	-81	-83	-171	-184	-215
Interest Expense	30	44	21	-	0.00	24	1.46
Interest & Investment Income	-158	-215	-74	-90	-143	-165	-156
Other Income / (Expense), net	3.38	15	14	6.30	-28	5.11	-57
Income Tax Expense	20	-1.37	59	-9.54	55	69	70
Basic Earnings per Share	($0.09)	($0.16)	$0.41	($0.83)	$0.18	$0.16	$0.27
Weighted Average Basic Shares Outstanding	232.40M	237.70M	279.23M	280.10M	281.01M	282.78M	283.96M
Diluted Earnings per Share	($0.09)	($0.16)	$0.41	($0.83)	$0.18	$0.16	$0.27
Weighted Average Diluted Shares Outstanding	232.40M	237.70M	279.38M	280.10M	283.22M	284.91M	286.42M
Weighted Average Basic & Diluted Shares Outstanding	-	-	282.93M	282.42M	282.83M	283.47M	284.39M

This table shows Sotera Health's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Period end date	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025	3/31/2026
Net Income / (Loss) Attributable to Common Shareholders	-14	39	6.32	8.75	17	12	-13	7.96	48	35	27
Consolidated Net Income / (Loss)	-14	74	6.32	8.75	17	12	-13	7.96	48	35	27
Net Income / (Loss) Continuing Operations	-14	74	6.32	8.75	17	12	-13	7.96	48	35	27
Total Pre-Tax Income	0.47	66	11	15	43	45	-15	19	73	70	43
Total Operating Income	76	104	53	77	81	87	57	54	111	170	76
Total Gross Profit	146	180	127	153	158	164	135	167	178	166	147
Total Revenue	263	310	248	277	285	290	255	294	311	303	280
Operating Revenue	263	310	248	277	285	290	255	294	311	303	280
Total Cost of Revenue	117	130	121	124	127	126	119	128	134	138	133
Operating Cost of Revenue	117	130	121	124	127	126	119	128	134	138	133
Total Operating Expenses	70	76	74	76	78	77	78	112	66	-4.41	71
Selling, General & Admin Expense	54	60	58	61	62	62	63	69	63	58	68
Amortization Expense	16	16	16	15	16	15	15	9.30	3.09	3.02	3.03
Total Other Income / (Expense), net	-76	-3.35	-42	-62	-38	-42	-72	-36	-38	-100	-33
Interest & Investment Income	-41	-43	-42	-40	-42	-41	-41	-41	-39	-35	-35
Other Income / (Expense), net	-35	39	-0.39	2.13	3.89	-0.52	-31	5.20	1.99	-64	1.53
Income Tax Expense	14	27	4.69	6.39	26	33	-1.56	11	25	36	16
Basic Earnings per Share	($0.05)	$0.14	$0.02	$0.03	$0.06	$0.05	($0.05)	$0.03	$0.17	$0.12	$0.09
Weighted Average Basic Shares Outstanding	281.11M	281.01M	281.91M	282.89M	283.06M	282.78M	283.56M	283.93M	284.07M	283.96M	284.89M
Diluted Earnings per Share	($0.05)	$0.14	$0.02	$0.03	$0.06	$0.05	($0.05)	$0.03	$0.17	$0.12	$0.09
Weighted Average Diluted Shares Outstanding	281.11M	283.22M	284.06M	284.54M	285.56M	284.91M	283.56M	285.76M	286.75M	286.42M	287.62M
Weighted Average Basic & Diluted Shares Outstanding	282.62M	282.83M	283.07M	283.21M	283.24M	283.47M	283.86M	284.05M	284.09M	284.39M	285.17M

This table details how cash moves in and out of Sotera Health's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Net Change in Cash & Equivalents	-34	39	4.47	289	-95	-23	68
Net Cash From Operating Activities	149	121	282	278	-148	224	287
Net Cash From Continuing Operating Activities	149	121	282	278	-148	224	287
Net Income / (Loss) Continuing Operations	-20	-37	117	-234	51	44	78
Consolidated Net Income / (Loss)	-20	-37	117	-234	51	44	78
Depreciation Expense	67	63	64	64	77	84	95
Amortization Expense	88	92	93	87	90	87	47
Non-Cash Adjustments To Reconcile Net Income	42	41	25	430	-337	4.88	74
Changes in Operating Assets and Liabilities, net	-27	-38	-18	-70	-29	4.01	-6.80
Net Cash From Investing Activities	-57	-159	-160	-182	-215	-179	-135
Net Cash From Continuing Investing Activities	-57	-159	-160	-182	-215	-179	-135
Purchase of Property, Plant & Equipment	-57	-54	-102	-182	-215	-179	-138
Other Investing Activities, net	0.00	0.00	-0.70	0.03	0.07	0.07	2.87
Net Cash From Financing Activities	-126	73	-117	198	266	-51	-101
Net Cash From Continuing Financing Activities	-126	73	-117	198	266	-51	-101
Repayment of Debt	-2,579	-1,199	-107	-1.85	-230	-2,299	-94
Issuance of Debt	3,145	150	0.00	200	500	2,259	0.00
Other Financing Activities, net	0.00	0.00	-1.43	-0.39	-4.09	-11	-6.57
Effect of Exchange Rate Changes	0.49	4.11	0.04	-4.46	2.04	-17	16
Cash Interest Paid	151	211	59	76	174	180	164
Cash Income Taxes Paid	45	24	52	75	50	66	61

This table details how cash moves in and out of Sotera Health's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Period end date	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025	3/31/2026
Net Change in Cash & Equivalents	-18	49	-39	-15	61	-30	27	28	-33	45	-31
Net Cash From Operating Activities	42	113	9.70	61	97	56	56	57	71	103	29
Net Cash From Continuing Operating Activities	42	113	9.70	61	97	56	56	57	71	103	29
Net Income / (Loss) Continuing Operations	-14	39	6.32	8.75	17	12	-13	7.96	48	35	27
Consolidated Net Income / (Loss)	-14	39	6.32	8.75	17	12	-13	7.96	48	35	27
Depreciation Expense	18	21	20	20	23	21	22	23	23	27	25
Amortization Expense	23	23	23	22	21	21	20	13	6.95	7.04	7.07
Non-Cash Adjustments To Reconcile Net Income	41	11	-32	31	11	-4.80	43	70	-33	9.06	-23
Changes in Operating Assets and Liabilities, net	-26	20	-7.84	-20	25	6.60	-16	-57	26	25	-6.74
Net Cash From Investing Activities	-52	-65	-35	-42	-36	-66	-20	-31	-33	-51	-45
Net Cash From Continuing Investing Activities	-52	-65	-35	-42	-36	-66	-20	-31	-33	-51	-45
Purchase of Property, Plant & Equipment	-52	-65	-35	-42	-36	-66	-20	-31	-36	-51	-46
Other Investing Activities, net	0.04	-	0.04	-	0.04	-	0.04	-	2.84	-	1.04
Net Cash From Financing Activities	-3.45	-3.79	-12	-29	-2.65	-6.55	-8.09	-6.93	-77	-8.18	-13
Net Cash From Continuing Financing Activities	-3.45	-3.79	-12	-29	-2.65	-6.55	-8.09	-6.93	-77	-8.18	-13
Repayment of Debt	-3.45	0.30	-3.05	-2,289	-2.65	-2.12	-4.49	-6.88	-77	-5.47	-3.98
Other Financing Activities, net	-	-4.09	-8.89	-	-	-4.43	-3.60	-0.05	-0.21	-2.71	-8.80
Effect of Exchange Rate Changes	-4.37	4.62	-1.74	-5.02	2.28	-13	-0.34	8.94	6.27	1.20	-2.04
Cash Interest Paid	72	23	70	41	32	37	47	55	27	34	37
Cash Income Taxes Paid	15	7.62	9.84	18	15	23	12	20	15	13	9.20

This table presents Sotera Health's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2020	2021	2022	2023	2024	2025
Period end date	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Total Assets	2,761	2,790	3,118	3,130	3,072	3,263
Total Current Assets	315	346	645	557	526	613
Cash & Equivalents	102	107	395	296	277	345
Restricted Cash	0.01	0.01	1.08	5.25	1.62	1.84
Accounts Receivable	92	108	118	148	140	139
Inventories, net	34	54	37	48	49	54
Prepaid Expenses	65	72	81	54	51	65
Current Deferred & Refundable Income Taxes	22	4.64	12	5.73	6.66	8.00
Plant, Property, & Equipment, net	610	651	775	947	1,037	1,131
Total Noncurrent Assets	1,836	1,793	1,698	1,626	1,509	1,519
Goodwill	1,116	1,120	1,102	1,111	1,081	1,103
Intangible Assets	643	599	491	416	318	288
Noncurrent Deferred & Refundable Income Taxes	8.42	5.89	4.10	4.99	2.87	3.85
Employee Benefit Assets	0.00	5.48	36	28	43	54
Other Noncurrent Operating Assets	55	53	65	65	65	70
Total Liabilities & Shareholders' Equity	2,761	2,790	3,118	3,130	3,072	3,263
Total Liabilities	2,307	2,203	2,767	2,687	2,667	2,657
Total Current Liabilities	141	161	792	231	191	250
Short-Term Debt	-	9.29	205	11	20	20
Accounts Payable	52	73	74	71	55	78
Accrued Expenses	61	62	490	122	90	125
Current Deferred Revenue	6.06	8.67	12	13	15	18
Current Deferred & Payable Income Tax Liabilities	10	6.70	5.87	4.15	7.56	5.69
Other Current Liabilities	11	1.78	4.62	8.77	2.92	3.47
Total Noncurrent Liabilities	2,152	2,042	1,976	2,456	2,476	2,408
Long-Term Debt	1,825	1,744	1,747	2,224	2,208	2,127
Capital Lease Obligations	-	41	57	64	95	94
Asset Retirement Reserve & Litigation Obligation	45	42	43	48	49	53
Noncurrent Deferred Revenue	21	21	19	19	17	17
Noncurrent Deferred & Payable Income Tax Liabilities	122	135	68	64	70	71
Noncurrent Employee Benefit Liabilities	48	11	7.91	8.44	7.86	8.12
Other Noncurrent Operating Liabilities	91	49	34	29	29	37
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	455	586	350	444	405	606
Total Preferred & Common Equity	452	586	350	444	405	606
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	452	586	350	444	405	606
Common Stock	1,169	1,175	1,192	1,218	1,247	1,265
Retained Earnings	-589	-472	-706	-654	-610	-532
Treasury Stock	-34	-34	-30	-27	-23	-17
Accumulated Other Comprehensive Income / (Loss)	-94	-84	-107	-93	-208	-110

This table presents Sotera Health's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q1 2023	Q2 2023	Q3 2023	Q1 2024	Q2 2024	Q3 2024	Q1 2025	Q2 2025	Q3 2025	Q1 2026
Period end date	9/30/2022	3/31/2023	6/30/2023	9/30/2023	3/31/2024	6/30/2024	9/30/2024	3/31/2025	6/30/2025	9/30/2025	3/31/2026
Total Assets	2,811	3,414	3,075	3,037	3,060	3,058	3,149	3,098	3,217	3,186	3,236
Total Current Assets	421	924	547	520	487	498	564	555	608	578	586
Cash & Equivalents	164	648	263	245	261	246	307	304	332	299	314
Restricted Cash	0.99	12	7.79	7.58	1.69	1.67	1.74	1.69	1.84	1.83	1.80
Accounts Receivable	112	109	117	118	111	124	130	128	137	142	137
Inventories, net	37	47	42	38	51	58	54	61	60	50	57
Prepaid Expenses	82	87	91	84	54	57	57	55	66	72	69
Current Deferred & Refundable Income Taxes	25	20	26	27	8.29	12	14	5.14	11	12	6.31
Plant, Property, & Equipment, net	704	816	859	884	979	995	1,026	1,046	1,080	1,094	1,143
Total Noncurrent Assets	1,685	1,674	1,669	1,633	1,593	1,566	1,559	1,496	1,528	1,514	1,506
Goodwill	1,092	1,103	1,110	1,101	1,103	1,098	1,105	1,084	1,105	1,099	1,098
Intangible Assets	504	472	456	429	390	368	352	300	300	291	279
Noncurrent Deferred & Refundable Income Taxes	5.09	4.17	4.16	4.04	4.88	4.75	4.95	2.98	4.47	3.22	3.77
Employee Benefit Assets	9.86	37	39	39	30	31	33	44	48	49	55
Other Noncurrent Operating Assets	74	58	59	59	65	64	65	64	71	72	71
Total Liabilities & Shareholders' Equity	2,811	3,414	3,075	3,037	3,060	3,058	3,149	3,098	3,217	3,186	3,236
Total Liabilities	2,204	3,053	2,657	2,659	2,630	2,635	2,679	2,683	2,705	2,636	2,613
Total Current Liabilities	140	600	200	201	152	170	196	226	246	242	208
Short-Term Debt	7.72	20	12	12	10	16	20	20	20	20	20
Accounts Payable	61	62	56	57	62	64	71	70	64	61	77
Accrued Expenses	57	497	103	106	62	69	83	114	144	140	86
Current Deferred Revenue	5.35	15	14	13	13	13	11	14	12	14	14
Current Deferred & Payable Income Tax Liabilities	7.35	4.59	5.73	4.14	4.51	4.41	8.34	5.39	3.94	4.32	8.40
Other Current Liabilities	2.12	2.11	9.40	8.65	1.49	2.77	2.82	3.04	3.24	3.35	3.58
Total Noncurrent Liabilities	2,064	2,453	2,456	2,459	2,478	2,465	2,483	2,457	2,459	2,393	2,406
Long-Term Debt	1,747	2,222	2,222	2,223	2,225	2,214	2,211	2,205	2,203	2,129	2,124
Capital Lease Obligations	55	82	61	84	91	94	98	94	95	95	93
Asset Retirement Reserve & Litigation Obligation	44	43	44	44	48	48	49	50	52	52	54
Noncurrent Deferred Revenue	19	19	19	18	18	18	18	17	17	17	17
Noncurrent Deferred & Payable Income Tax Liabilities	152	63	68	69	60	54	64	54	48	54	75
Noncurrent Employee Benefit Liabilities	10	7.86	8.01	7.76	8.24	8.18	8.22	7.91	8.30	8.12	7.98
Other Noncurrent Operating Liabilities	38	15	33	12	28	30	35	29	35	38	35
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	607	361	418	377	429	423	470	414	511	550	623
Total Preferred & Common Equity	607	361	418	377	429	423	470	414	511	550	623
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	607	361	418	377	429	423	470	414	511	550	623
Common Stock	1,189	1,198	1,206	1,213	1,223	1,232	1,242	1,248	1,254	1,262	1,266
Retained Earnings	-386	-703	-679	-693	-648	-639	-622	-623	-615	-567	-506
Treasury Stock	-33	-29	-29	-28	-26	-25	-25	-21	-19	-19	-12
Accumulated Other Comprehensive Income / (Loss)	-164	-105	-79	-114	-120	-145	-125	-189	-108	-126	-126

This table displays calculated financial ratios and metrics derived from Sotera Health's official financial filings.

Metric	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Growth Metrics	-	-	-	-	-	-	-
Revenue Growth	0.00%	5.12%	13.85%	-100.00%	0.00%	4.88%	5.74%
EBITDA Growth	0.00%	9.90%	13.78%	-5.09%	11.09%	5.04%	-5.65%
EBIT Growth	0.00%	18.01%	22.63%	-5.89%	11.49%	6.63%	0.65%
NOPAT Growth	0.00%	12.21%	18.66%	1.59%	-22.88%	-13.45%	64.87%
Net Income Growth	0.00%	-83.55%	412.40%	-420.57%	123.01%	-48.60%	75.57%
EPS Growth	0.00%	-77.78%	356.25%	-302.44%	121.69%	-11.11%	68.75%
Operating Cash Flow Growth	0.00%	-19.09%	133.48%	-1.27%	-153.15%	251.74%	28.12%
Free Cash Flow Firm Growth	0.00%	0.00%	104.20%	456.08%	-172.38%	131.16%	31.50%
Invested Capital Growth	0.00%	0.00%	3.94%	-13.29%	24.33%	0.37%	2.06%
Revenue Q/Q Growth	0.00%	0.00%	2.69%	-100.00%	5.92%	-1.79%	1.15%
EBITDA Q/Q Growth	0.00%	0.00%	4.23%	-3.38%	1,123.75%	-4.70%	2.67%
EBIT Q/Q Growth	0.00%	0.00%	6.72%	-4.71%	238.05%	-6.69%	6.73%
NOPAT Q/Q Growth	0.00%	0.00%	53.03%	8.52%	-17.74%	-29.82%	50.98%
Net Income Q/Q Growth	0.00%	0.00%	210.35%	-407.38%	128.13%	-37.25%	40.64%
EPS Q/Q Growth	0.00%	0.00%	272.73%	-293.02%	116.36%	-36.00%	35.00%
Operating Cash Flow Q/Q Growth	0.00%	0.00%	18.78%	14.68%	7.05%	-20.39%	19.76%
Free Cash Flow Firm Q/Q Growth	0.00%	0.00%	0.00%	420.01%	-1,074.23%	-9.34%	12.84%
Invested Capital Q/Q Growth	0.00%	0.00%	3.73%	-12.81%	-0.12%	-1.66%	0.30%
Profitability Metrics	-	-	-	-	-	-	-
Gross Margin	50.81%	54.22%	55.68%	0.00%	55.00%	54.73%	55.48%
EBITDA Margin	43.94%	45.94%	45.91%	0.00%	42.97%	43.04%	38.40%
Operating Margin	23.59%	25.18%	27.56%	0.00%	26.37%	27.05%	31.11%
EBIT Margin	24.02%	26.97%	29.05%	0.00%	27.06%	27.51%	26.18%
Profit (Net Income) Margin	-2.62%	-4.58%	12.57%	0.00%	8.23%	4.03%	6.70%
Tax Burden Percent	2,229.80%	96.48%	66.65%	154.44%	81.47%	38.99%	52.84%
Interest Burden Percent	-0.49%	-17.61%	64.94%	-95.47%	37.35%	37.62%	48.41%
Effective Tax Rate	0.00%	0.00%	33.35%	0.00%	51.54%	61.01%	47.16%
Return on Invested Capital (ROIC)	0.00%	13.24%	7.71%	0.00%	6.09%	4.75%	7.73%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	-7.85%	4.53%	0.00%	3.45%	1.20%	1.97%
Return on Net Nonoperating Assets (RNNOA)	0.00%	-29.74%	14.80%	0.00%	15.67%	5.72%	7.69%
Return on Equity (ROE)	0.00%	-16.50%	22.51%	-80.20%	21.76%	10.46%	15.42%
Cash Return on Invested Capital (CROIC)	0.00%	-186.76%	3.84%	22.46%	-15.60%	4.38%	5.69%
Operating Return on Assets (OROA)	0.00%	7.99%	9.75%	0.00%	9.09%	9.76%	9.62%
Return on Assets (ROA)	0.00%	-1.36%	4.22%	0.00%	2.76%	1.43%	2.46%
Return on Common Equity (ROCE)	0.00%	-16.41%	22.46%	-80.20%	21.76%	10.46%	15.42%
Return on Equity Simple (ROE_SIMPLE)	0.00%	-8.29%	19.98%	-107.20%	19.47%	10.96%	0.00%
Net Operating Profit after Tax (NOPAT)	129	144	171	174	134	116	191
NOPAT Margin	16.51%	17.63%	18.37%	0.00%	12.78%	10.54%	16.44%
Net Nonoperating Expense Percent (NNEP)	0.00%	21.09%	3.18%	33.39%	2.64%	3.55%	5.76%
Return On Investment Capital (ROIC_SIMPLE)	-	-	-	7.37%	4.89%	4.25%	6.72%
Cost of Revenue to Revenue	49.19%	45.78%	44.32%	0.00%	45.00%	45.27%	44.52%
SG&A Expenses to Revenue	18.95%	21.82%	21.27%	0.00%	22.56%	22.05%	21.72%
R&D to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Expenses to Revenue	27.22%	29.04%	28.12%	0.00%	28.64%	27.69%	24.36%
Earnings before Interest and Taxes (EBIT)	187	221	271	255	284	303	305
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	342	376	428	406	451	474	447
Valuation Ratios	-	-	-	-	-	-	-
Price to Book Value (P/BV)	0.00	2.83	11.37	6.71	10.73	9.57	8.27
Price to Tangible Book Value (P/TBV)	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Price to Revenue (P/Rev)	1.38	1.56	7.15	0.00	4.54	3.52	4.31
Price to Earnings (P/E)	0.00	0.00	57.00	0.00	92.69	87.27	64.29
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	1.75%	0.00%	1.08%	1.15%	1.56%
Enterprise Value to Invested Capital (EV/IC)	0.00	1.37	3.68	2.02	2.77	2.42	2.76
Enterprise Value to Revenue (EV/Rev)	0.00	3.65	8.95	0.00	6.44	5.38	5.93
Enterprise Value to EBITDA (EV/EBITDA)	0.00	7.96	19.50	9.76	14.99	12.50	15.45
Enterprise Value to EBIT (EV/EBIT)	0.00	13.55	30.82	15.56	23.81	19.55	22.66
Enterprise Value to NOPAT (EV/NOPAT)	0.00	20.73	48.74	22.79	50.41	51.01	36.09
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	24.79	29.62	14.26	0.00	26.41	24.04
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	97.71	8.35	0.00	55.30	49.06
Leverage & Solvency	-	-	-	-	-	-	-
Debt to Equity	0.00	4.01	3.06	5.74	5.18	5.74	3.70
Long-Term Debt to Equity	0.00	4.01	3.04	5.15	5.16	5.69	3.66
Financial Leverage	0.00	3.79	3.27	3.51	4.55	4.76	3.90
Leverage Ratio	0.00	6.07	5.33	6.31	7.87	7.31	6.27
Compound Leverage Factor	0.00	-1.07	3.46	-6.02	2.94	2.75	3.03
Debt to Total Capital	0.00%	80.06%	75.37%	85.15%	83.82%	85.16%	78.71%
Short-Term Debt to Total Capital	0.00%	0.00%	0.39%	8.68%	0.39%	0.73%	0.69%
Long-Term Debt to Total Capital	0.00%	80.06%	74.98%	76.48%	83.43%	84.43%	78.02%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.10%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	0.00%	19.84%	24.63%	14.85%	16.18%	14.84%	21.29%
Debt to EBITDA	0.00	4.86	4.19	4.95	5.10	4.91	5.01
Net Debt to EBITDA	0.00	4.55	3.92	3.97	4.43	4.32	4.24
Long-Term Debt to EBITDA	0.00	4.86	4.17	4.44	5.07	4.86	4.97
Debt to NOPAT	0.00	12.65	10.48	11.55	17.14	20.02	11.71
Net Debt to NOPAT	0.00	11.85	9.80	9.28	14.89	17.62	9.90
Long-Term Debt to NOPAT	0.00	12.65	10.43	10.38	17.06	19.85	11.61
Altman Z-Score	0.00	0.67	2.31	0.41	1.53	1.41	1.70
Noncontrolling Interest Sharing Ratio	0.00%	0.50%	0.22%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-
Current Ratio	0.00	2.24	2.15	0.81	2.42	2.75	2.46
Quick Ratio	0.00	1.38	1.33	0.65	1.93	2.19	1.94
Cash Flow Metrics	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	0.00	-2,033	85	475	-344	107	141
Operating Cash Flow to CapEx	260.30%	225.36%	275.59%	152.41%	-68.72%	125.18%	208.09%
Free Cash Flow to Firm to Interest Expense	0.00	-45.94	4.13	0.00	0.00	4.43	96.27
Operating Cash Flow to Interest Expense	4.94	2.72	13.61	0.00	0.00	9.28	196.44
Operating Cash Flow Less CapEx to Interest Expense	3.04	1.52	8.67	0.00	0.00	1.87	102.04
Efficiency Ratios	-	-	-	-	-	-	-
Asset Turnover	0.00	0.30	0.34	0.00	0.34	0.35	0.37
Accounts Receivable Turnover	0.00	8.92	9.32	0.00	7.88	7.64	8.32
Inventory Turnover	0.00	10.99	9.34	9.77	11.05	10.22	10.01
Fixed Asset Turnover	0.00	1.34	1.48	0.00	1.22	1.11	1.07
Accounts Payable Turnover	0.00	7.15	6.59	6.08	6.50	7.90	7.79
Days Sales Outstanding (DSO)	0.00	40.93	39.17	0.00	46.30	47.77	43.86
Days Inventory Outstanding (DIO)	0.00	33.22	39.07	37.36	33.03	35.71	36.47
Days Payable Outstanding (DPO)	0.00	51.06	55.38	60.06	56.12	46.21	46.87
Cash Conversion Cycle (CCC)	0.00	23.09	22.86	0.00	23.21	37.27	33.46
Capital & Investment Metrics	-	-	-	-	-	-	-
Invested Capital	0.00	2,178	2,263	1,963	2,440	2,449	2,500
Invested Capital Turnover	0.00	0.75	0.42	0.00	0.48	0.45	0.47
Increase / (Decrease) in Invested Capital	0.00	2,178	86	-301	478	9.01	51
Enterprise Value (EV)	0.00	2,990	8,340	3,962	6,759	5,919	6,905
Market Capitalization	1,072	1,279	6,663	2,350	4,762	3,875	5,011
Book Value per Share	$0.00	$1.90	$2.07	$1.24	$1.57	$1.43	$2.13
Tangible Book Value per Share	$0.00	($5.50)	($4.00)	($4.41)	($3.83)	($3.51)	($2.76)
Total Capital	0.00	2,279	2,380	2,359	2,742	2,728	2,846
Total Debt	0.00	1,825	1,794	2,009	2,298	2,323	2,240
Total Long-Term Debt	0.00	1,825	1,784	1,804	2,287	2,303	2,221
Net Debt	0.00	1,709	1,677	1,612	1,997	2,044	1,894
Capital Expenditures (CapEx)	57	54	102	182	215	179	138
Debt-free, Cash-free Net Working Capital (DFCFNWC)	0.00	72	87	-338	36	76	37
Debt-free Net Working Capital (DFNWC)	0.00	174	194	58	337	355	384
Net Working Capital (NWC)	0.00	174	185	-147	327	335	364
Net Nonoperating Expense (NNE)	149	182	54	549	48	72	113
Net Nonoperating Obligations (NNO)	0.00	1,723	1,677	1,612	1,997	2,044	1,894
Total Depreciation and Amortization (D&A)	155	155	157	151	167	171	142
Debt-free, Cash-free Net Working Capital to Revenue	0.00%	8.80%	9.36%	0.00%	3.40%	6.91%	3.19%
Debt-free Net Working Capital to Revenue	0.00%	21.32%	20.84%	0.00%	32.15%	32.25%	32.96%
Net Working Capital to Revenue	0.00%	21.32%	19.84%	0.00%	31.12%	30.45%	31.27%
Earnings Adjustments	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$0.00	$0.00	$0.41	($0.83)	$0.18	$0.16	$0.27
Adjusted Weighted Average Basic Shares Outstanding	0.00	0.00	279.23M	280.10M	281.01M	282.78M	283.96M
Adjusted Diluted Earnings per Share	$0.00	$0.00	$0.41	($0.83)	$0.18	$0.16	$0.27
Adjusted Weighted Average Diluted Shares Outstanding	0.00	0.00	279.38M	280.10M	283.22M	284.91M	286.42M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	0.00	0.00	282.93M	282.42M	282.83M	283.47M	284.39M
Normalized Net Operating Profit after Tax (NOPAT)	133	144	171	174	194	208	191
Normalized NOPAT Margin	17.03%	17.63%	18.37%	0.00%	18.46%	18.93%	16.44%
Pre Tax Income Margin	-0.12%	-4.75%	18.86%	0.00%	10.10%	10.35%	12.68%
Debt Service Ratios	-	-	-	-	-	-	-
EBIT to Interest Expense	6.20	4.99	13.08	0.00	0.00	12.53	208.41
NOPAT to Interest Expense	4.26	3.26	8.27	0.00	0.00	4.80	130.86
EBIT Less CapEx to Interest Expense	4.30	3.78	8.14	0.00	0.00	5.12	114.00
NOPAT Less CapEx to Interest Expense	2.36	2.05	3.33	0.00	0.00	-2.61	36.46
Payout Ratios	-	-	-	-	-	-	-
Dividend Payout Ratio	-3,383.94%	0.00%	7.19%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	-3,383.94%	-90.69%	7.19%	0.00%	0.00%	0.00%	0.00%

This table displays calculated financial ratios and metrics derived from Sotera Health's official financial filings.

Metric	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Period end date	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025	3/31/2026
DEI Shares Outstanding	-	-	-	-	-	-	-	-	-	-	284,392,079.00
DEI Adjusted Shares Outstanding	-	-	-	-	-	-	-	-	-	-	284,392,079.00
DEI Earnings Per Adjusted Shares Outstanding	-	-	-	-	-	-	-	-	-	-	0.09
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	5.82%	141.25%	12.51%	8.35%	8.47%	-6.46%	2.56%	6.42%	9.05%	4.56%	10.03%
EBITDA Growth	-20.67%	87.23%	26.45%	13.12%	57.58%	-31.28%	-28.85%	-20.60%	10.97%	9.08%	60.93%
EBIT Growth	-37.20%	132.04%	54.02%	21.03%	105.36%	-39.56%	-50.64%	-24.45%	34.09%	22.19%	196.93%
NOPAT Growth	-5,960.81%	45.48%	73.90%	3.03%	101.45%	-61.02%	-40.15%	-48.35%	130.50%	252.51%	18.49%
Net Income Growth	-154.44%	115.96%	122.48%	-62.77%	224.44%	-83.28%	-309.71%	-9.05%	184.74%	182.78%	300.52%
EPS Growth	-155.56%	112.28%	100.00%	-62.50%	220.00%	-64.29%	-350.00%	0.00%	183.33%	140.00%	280.00%
Operating Cash Flow Growth	-38.26%	10.99%	-71.36%	118.21%	132.87%	-50.75%	472.44%	-6.33%	-26.99%	85.05%	-46.98%
Free Cash Flow Firm Growth	-7,606.69%	-221.41%	-232.50%	89.29%	99.36%	103.57%	119.00%	351.85%	569.57%	126.07%	-166.03%
Invested Capital Growth	8.54%	24.33%	23.06%	2.23%	1.94%	0.37%	-2.60%	-0.10%	0.08%	2.06%	4.79%
Revenue Q/Q Growth	3.09%	17.88%	-20.00%	11.45%	3.21%	1.66%	-12.29%	15.64%	5.77%	-2.53%	-7.71%
EBITDA Q/Q Growth	-23.59%	128.42%	-36.83%	26.30%	6.44%	-0.39%	-46.86%	40.94%	48.76%	-2.09%	-21.60%
EBIT Q/Q Growth	-36.98%	248.74%	-51.27%	49.53%	6.93%	2.64%	-69.92%	128.87%	89.79%	-6.48%	-26.91%
NOPAT Q/Q Growth	-5,232.20%	102.77%	-50.18%	45.45%	-27.91%	-25.38%	-23.50%	25.52%	221.70%	14.12%	-43.80%
Net Income Q/Q Growth	-158.10%	639.39%	-83.65%	38.45%	94.17%	-27.50%	-207.60%	160.05%	507.89%	-28.00%	-23.70%
EPS Q/Q Growth	-162.50%	380.00%	-85.71%	50.00%	100.00%	-16.67%	-200.00%	160.00%	466.67%	-29.41%	-25.00%
Operating Cash Flow Q/Q Growth	112.43%	170.31%	-91.43%	531.97%	58.99%	-42.83%	-0.35%	3.41%	23.93%	44.90%	-71.45%
Free Cash Flow Firm Q/Q Growth	-2,452.32%	82.68%	-4.85%	97.69%	-51.57%	197.27%	457.79%	-69.38%	182.61%	-53.17%	-305.45%
Invested Capital Q/Q Growth	-0.01%	-0.12%	2.13%	0.23%	-0.30%	-1.66%	-0.89%	2.80%	-0.12%	0.30%	1.76%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	55.47%	58.05%	51.22%	55.24%	55.36%	56.64%	53.21%	56.61%	57.04%	54.68%	52.52%
EBITDA Margin	31.04%	60.14%	38.58%	43.72%	45.09%	44.18%	26.77%	32.62%	45.88%	46.09%	39.15%
Operating Margin	28.92%	33.53%	21.43%	27.77%	28.20%	30.03%	10.25%	18.49%	35.71%	56.13%	27.08%
EBIT Margin	15.62%	46.20%	21.27%	28.54%	29.56%	29.85%	10.24%	20.26%	36.35%	34.88%	27.62%
Profit (Net Income) Margin	-5.19%	23.75%	2.55%	3.16%	5.95%	4.25%	-5.21%	2.71%	15.55%	11.48%	9.49%
Tax Burden Percent	-2,906.38%	112.20%	57.41%	57.81%	39.76%	27.41%	89.46%	42.13%	66.36%	49.43%	62.40%
Interest Burden Percent	1.14%	45.82%	20.87%	19.18%	50.66%	51.91%	-56.90%	31.69%	64.45%	66.61%	55.09%
Effective Tax Rate	3,006.38%	41.10%	42.59%	42.19%	60.24%	72.59%	0.00%	57.87%	33.64%	50.57%	37.60%
Return on Invested Capital (ROIC)	-354.70%	9.41%	5.86%	7.13%	5.09%	3.70%	3.23%	3.51%	10.94%	13.05%	8.08%
ROIC Less NNEP Spread (ROIC-NNEP)	-236.21%	10.10%	4.57%	5.40%	4.36%	3.13%	1.68%	2.77%	9.66%	10.54%	7.03%
Return on Net Nonoperating Assets (RNNOA)	-890.40%	45.91%	21.52%	26.31%	21.01%	14.91%	8.13%	12.05%	37.51%	41.06%	26.68%
Return on Equity (ROE)	-1,245.10%	55.33%	27.39%	33.44%	26.10%	18.62%	11.36%	15.56%	48.45%	54.11%	34.76%
Cash Return on Invested Capital (CROIC)	-1.25%	-15.60%	-14.23%	3.25%	4.79%	4.38%	5.73%	2.70%	5.01%	5.69%	4.12%
Operating Return on Assets (OROA)	5.29%	15.52%	7.08%	10.22%	10.71%	10.59%	3.68%	7.26%	13.20%	12.81%	10.37%
Return on Assets (ROA)	-1.76%	7.98%	0.85%	1.13%	2.16%	1.51%	-1.87%	0.97%	5.65%	4.22%	3.57%
Return on Common Equity (ROCE)	-1,245.10%	55.33%	27.39%	33.44%	26.10%	18.62%	11.36%	15.56%	48.45%	54.11%	34.76%
Return on Equity Simple (ROE_SIMPLE)	-81.34%	0.00%	12.78%	9.48%	15.05%	0.00%	5.99%	0.00%	0.00%	0.00%	0.00%
Net Operating Profit after Tax (NOPAT)	-2,212	61	31	44	32	24	18	23	74	84	47
NOPAT Margin	-840.38%	19.75%	12.30%	16.05%	11.21%	8.23%	7.18%	7.79%	23.70%	27.75%	16.89%
Net Nonoperating Expense Percent (NNEP)	-118.49%	-0.69%	1.30%	1.74%	0.73%	0.57%	1.55%	0.74%	1.28%	2.51%	1.05%
Return On Investment Capital (ROIC_SIMPLE)	-	2.23%	-	-	-	0.88%	0.67%	0.81%	2.64%	2.96%	1.65%
Cost of Revenue to Revenue	44.53%	41.95%	48.78%	44.76%	44.64%	43.36%	46.79%	43.39%	42.96%	45.32%	47.48%
SG&A Expenses to Revenue	20.56%	19.46%	23.45%	21.90%	21.72%	21.31%	24.78%	23.41%	20.33%	18.95%	24.36%
R&D to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Expenses to Revenue	26.55%	24.52%	29.79%	27.47%	27.15%	26.61%	42.96%	38.12%	21.32%	-1.45%	25.44%
Earnings before Interest and Taxes (EBIT)	41	143	53	79	84	87	26	60	113	106	77
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	82	187	96	121	129	128	68	96	143	140	110
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	11.22	10.73	7.90	7.95	10.06	9.57	7.98	6.17	8.12	8.27	6.55
Price to Tangible Book Value (P/TBV)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Price to Revenue (P/Rev)	4.27	4.54	3.15	3.06	4.22	3.52	2.99	2.81	3.88	4.31	3.43
Price to Earnings (P/E)	0.00	92.69	61.88	83.80	66.84	87.27	133.20	131.39	80.61	64.29	34.62
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	1.08%	1.62%	1.19%	1.50%	1.15%	0.75%	0.76%	1.24%	1.56%	2.89%
Enterprise Value to Invested Capital (EV/IC)	2.58	2.77	2.19	2.18	2.71	2.42	2.19	2.06	2.57	2.76	2.36
Enterprise Value to Revenue (EV/Rev)	6.36	6.44	5.07	4.95	6.02	5.38	4.81	4.57	5.57	5.93	5.05
Enterprise Value to EBITDA (EV/EBITDA)	0.00	14.99	12.52	12.08	13.58	12.50	11.93	12.21	14.73	15.45	12.29
Enterprise Value to EBIT (EV/EBIT)	0.00	23.81	20.41	19.33	20.81	19.55	19.27	20.03	22.45	22.66	16.85
Enterprise Value to NOPAT (EV/NOPAT)	38.65	50.41	37.46	40.34	40.82	51.01	69.74	79.15	50.59	36.09	27.41
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	24.05	23.97	26.41	19.70	19.32	26.73	24.04	22.98
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	67.74	57.18	55.30	37.74	76.25	51.39	49.06	58.53
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	6.14	5.18	5.42	5.49	4.95	5.74	5.60	4.53	4.07	3.70	3.59
Long-Term Debt to Equity	6.11	5.16	5.39	5.46	4.91	5.69	5.55	4.49	4.04	3.66	3.56
Financial Leverage	3.77	4.55	4.71	4.87	4.82	4.76	4.83	4.35	3.88	3.90	3.80
Leverage Ratio	5.94	7.87	8.19	7.29	7.30	7.31	7.30	6.72	6.21	6.27	6.11
Compound Leverage Factor	0.07	3.61	1.71	1.40	3.70	3.79	-4.15	2.13	4.00	4.17	3.37
Debt to Total Capital	86.00%	83.82%	84.41%	84.60%	83.20%	85.16%	84.85%	81.93%	80.29%	78.71%	78.23%
Short-Term Debt to Total Capital	0.43%	0.39%	0.37%	0.58%	0.72%	0.73%	0.73%	0.72%	0.70%	0.69%	0.69%
Long-Term Debt to Total Capital	85.57%	83.43%	84.05%	84.02%	82.49%	84.43%	84.12%	81.21%	79.59%	78.02%	77.54%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	14.00%	16.18%	15.59%	15.40%	16.80%	14.84%	15.15%	18.07%	19.71%	21.29%	21.77%
Debt to EBITDA	-52.64	5.10	5.34	5.16	4.69	4.91	5.20	5.51	5.15	5.01	4.58
Net Debt to EBITDA	-46.90	4.43	4.73	4.61	4.07	4.32	4.51	4.71	4.46	4.24	3.93
Long-Term Debt to EBITDA	-52.37	5.07	5.31	5.13	4.65	4.86	5.16	5.46	5.11	4.97	4.54
Debt to NOPAT	14.22	17.14	15.96	17.24	14.08	20.02	30.41	35.70	17.70	11.71	10.22
Net Debt to NOPAT	12.67	14.89	14.16	15.40	12.22	17.62	26.40	30.55	15.33	9.90	8.78
Long-Term Debt to NOPAT	14.15	17.06	15.89	17.12	13.96	19.85	30.15	35.38	17.55	11.61	10.13
Altman Z-Score	1.13	1.38	1.02	1.05	1.37	1.18	0.97	0.98	1.37	1.50	1.30
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	2.59	2.42	3.20	2.93	2.88	2.75	2.46	2.47	2.38	2.46	2.82
Quick Ratio	1.81	1.93	2.44	2.18	2.23	2.19	1.91	1.90	1.82	1.94	2.17
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-2,404	-416	-436	-10	-15	15	83	25	72	34	-69
Operating Cash Flow to CapEx	80.46%	174.50%	27.80%	146.22%	267.81%	84.59%	278.75%	183.85%	196.71%	203.37%	63.76%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	-0.43	-218.40	0.00	0.00	317.53	66.04	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00	2.62	1,392.19	0.00	0.00	717.70	65.46	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00	0.83	872.34	0.00	0.00	327.34	32.18	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.34	0.34	0.33	0.36	0.36	0.35	0.36	0.36	0.36	0.37	0.38
Accounts Receivable Turnover	8.61	7.88	9.78	9.11	9.02	7.64	9.26	8.64	8.44	8.32	8.96
Inventory Turnover	12.04	11.05	9.87	9.85	10.97	10.22	8.83	8.49	9.78	10.01	8.98
Fixed Asset Turnover	1.25	1.22	1.20	1.18	1.17	1.11	1.09	1.08	1.09	1.07	1.09
Accounts Payable Turnover	7.67	6.50	7.84	8.20	7.86	7.90	7.54	7.81	7.66	7.79	7.25
Days Sales Outstanding (DSO)	42.37	46.30	37.32	40.04	40.48	47.77	39.43	42.23	43.23	43.86	40.72
Days Inventory Outstanding (DIO)	30.32	33.03	36.97	37.07	33.26	35.71	41.34	43.00	37.30	36.47	40.67
Days Payable Outstanding (DPO)	47.60	56.12	46.56	44.52	46.45	46.21	48.43	46.77	47.62	46.87	50.36
Cash Conversion Cycle (CCC)	25.10	23.21	27.73	32.59	27.29	37.27	32.33	38.46	32.91	33.46	31.03
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	2,443	2,440	2,492	2,498	2,491	2,449	2,427	2,496	2,493	2,500	2,544
Invested Capital Turnover	0.42	0.48	0.48	0.44	0.45	0.45	0.45	0.45	0.46	0.47	0.48
Increase / (Decrease) in Invested Capital	192	478	467	54	47	9.01	-65	-2.47	1.99	51	116
Enterprise Value (EV)	6,299	6,759	5,457	5,435	6,750	5,919	5,319	5,141	6,410	6,905	6,000
Market Capitalization	4,234	4,762	3,394	3,360	4,730	3,875	3,305	3,156	4,468	5,011	4,078
Book Value per Share	$1.34	$1.57	$1.52	$1.49	$1.66	$1.43	$1.46	$1.80	$1.94	$2.13	$2.19
Tangible Book Value per Share	($4.08)	($3.83)	($3.77)	($3.69)	($3.48)	($3.51)	($3.42)	($3.15)	($2.96)	($2.76)	($2.65)
Total Capital	2,696	2,742	2,755	2,746	2,799	2,728	2,734	2,830	2,794	2,846	2,860
Total Debt	2,318	2,298	2,326	2,323	2,329	2,323	2,319	2,318	2,243	2,240	2,237
Total Long-Term Debt	2,307	2,287	2,315	2,307	2,309	2,303	2,300	2,298	2,224	2,221	2,218
Net Debt	2,066	1,997	2,063	2,075	2,020	2,044	2,013	1,984	1,942	1,894	1,921
Capital Expenditures (CapEx)	52	65	35	42	36	66	20	31	36	51	46
Debt-free, Cash-free Net Working Capital (DFCFNWC)	78	36	82	96	80	76	43	48	54	37	82
Debt-free Net Working Capital (DFNWC)	331	337	345	344	388	355	349	382	355	384	398
Net Working Capital (NWC)	319	327	335	328	368	335	329	362	335	364	378
Net Nonoperating Expense (NNE)	-2,198	-12	24	36	15	12	32	15	25	49	21
Net Nonoperating Obligations (NNO)	2,066	1,997	2,063	2,075	2,020	2,044	2,013	1,984	1,942	1,894	1,921
Total Depreciation and Amortization (D&A)	41	43	43	42	44	42	42	36	30	34	32
Debt-free, Cash-free Net Working Capital to Revenue	7.89%	3.40%	7.63%	8.76%	7.11%	6.91%	3.87%	4.27%	4.69%	3.19%	6.90%
Debt-free Net Working Capital to Revenue	33.38%	32.15%	32.03%	31.32%	34.64%	32.25%	31.52%	33.99%	30.86%	32.96%	33.46%
Net Working Capital to Revenue	32.21%	31.12%	31.09%	29.87%	32.85%	30.45%	29.73%	32.18%	29.16%	31.27%	31.80%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($0.05)	$0.14	$0.02	$0.03	$0.06	$0.05	($0.05)	$0.03	$0.17	$0.12	$0.09
Adjusted Weighted Average Basic Shares Outstanding	281.11M	281.01M	281.91M	282.89M	283.06M	282.78M	283.56M	283.93M	284.07M	283.96M	284.89M
Adjusted Diluted Earnings per Share	($0.05)	$0.14	$0.02	$0.03	$0.06	$0.05	($0.05)	$0.03	$0.17	$0.12	$0.09
Adjusted Weighted Average Diluted Shares Outstanding	281.11M	283.22M	284.06M	284.54M	285.56M	284.91M	283.56M	285.76M	286.75M	286.42M	287.62M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	282.62M	282.83M	283.07M	283.21M	283.24M	283.47M	283.86M	284.05M	284.09M	284.39M	285.17M
Normalized Net Operating Profit after Tax (NOPAT)	53	61	31	44	56	61	40	62	74	119	47
Normalized NOPAT Margin	20.24%	19.75%	12.30%	16.05%	19.74%	21.02%	15.69%	21.03%	23.70%	39.29%	16.89%
Pre Tax Income Margin	0.18%	21.17%	4.44%	5.47%	14.98%	15.49%	-5.82%	6.42%	23.43%	23.23%	15.22%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00	3.37	1,205.66	0.00	0.00	745.35	104.11	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	0.00	1.90	457.25	0.00	0.00	286.67	67.87	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00	1.58	685.81	0.00	0.00	354.99	70.83	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00	0.11	-62.59	0.00	0.00	-103.70	34.60	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Financials Breakdown Chart

Key Financial Trends

Below is a concise, investor‑focused read on Sotera Health (SHC) using the latest quarterly data across the last four years. The highlights focus on notable trends in revenue, profitability, cash flow, and balance sheet strength.

Strongest quarterly cash flow from operations in Q4 2025: Net cash from continuing operating activities was about 103,104,000 USD in Q4 2025, the best among the recent four quarters and a sign of improving cash generation from core operations.
Operating profitability improving into Q4 2025: Total Operating Income reached 170,326,000 USD in Q4 2025, up from 111,177,000 USD in Q3 2025, signaling a rebound in core earnings.
Gross margin remained solid in the mid‑50s%: Q4 2025 gross profit of 165,920,000 USD on 303,441,000 USD revenue yields a gross margin of about 54.8%, consistent with historical levels.
Net income and earnings per share improving in late 2025: Net income attributable to common shareholders was 34,847,000 USD in Q4 2025 (EPS diluted 0.12 USD), marking a positive quarterly result after earlier volatility.
Balance sheet equity showing strength growth: Total Common Equity rose to about 550,471,000 USD by Q3 2025, up from roughly 511,283,000 USD in Q2 2025, indicating strengthening book value.
Free cash flow turning positive in Q4 2025: With CFO of 103.1M USD and capex around 50.7M USD, approximate free cash flow was still positive, supporting liquidity and debt management.
Q4 2025 revenue remained robust around $303M: Revenue of 303.441M USD in Q4 2025 demonstrates the company’s ability to sustain a sizable quarterly top line.
Operating cash generation supports capacity to fund capex: Higher cash from operations in late 2025 aligns with the uptick in capital expenditures, suggesting constructive reinvestment in capacity.

Capital expenditures rising modestly: Capex progressed toward the 50–51M USD level in Q4 2025, after mid‑single‑digit to tens of millions in earlier quarters, indicating ongoing investment in facilities and equipment.
Revenue and earnings exhibit quarterly volatility: Quarterly results swing between periods of stronger and weaker profitability (e.g., Q1 2025 and Q3/Q4 2025), reflecting seasonality or mix changes rather than a straight line trend.

Debt repayments and financing outflows remain meaningful: Net cash from financing activities were negative in several quarters (e.g., Q3 2025 and other periods), reflecting debt repayments and financing activity that reduce near‑term cash
Q1 2025 showed a negative net income print: Net income attributable to common shareholders was negative in Q1 2025, highlighting quarterly earnings volatility
High leverage remains a concern: Long‑term debt and other liabilities are sizable across periods, contributing to a substantial liabilities base relative to equity

05/11/26 05:05 PM ETAI Generated. May Contain Errors.

Sotera Health Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Sotera Health's financial year ends in December. Their financial year 2025 ended on December 31, 2025.

Sotera Health's net income appears to be on a downward trend, with a most recent value of $77.95 million in 2025, falling from -$20.43 million in 2019. The previous period was $44.40 million in 2024. Check out Sotera Health's forecast to explore projected trends and price targets.

Sotera Health's total operating income in 2025 was $362.03 million, based on the following breakdown:

Total Gross Profit: $645.53 million
Total Operating Expenses: $283.50 million

Over the last 6 years, Sotera Health's total revenue changed from $778.33 million in 2019 to $1.16 billion in 2025, a change of 49.5%.

Sotera Health's total liabilities were at $2.66 billion at the end of 2025, a 0.4% decrease from 2024, and a 15.2% increase since 2020.

In the past 5 years, Sotera Health's cash and equivalents has ranged from $102.45 million in 2020 to $395.21 million in 2022, and is currently $344.62 million as of their latest financial filing in 2025.

Over the last 6 years, Sotera Health's book value per share changed from 0.00 in 2019 to 2.13 in 2025, a change of 213.3%.

Related Companies

Financial statements for NASDAQ:SHC last updated on 5/8/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Sotera Health (SHC) Financials

Financials Breakdown Chart

Key Financial Trends

Sotera Health Financials - Frequently Asked Questions

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Sotera Health (SHC) Financials

Annual Income Statements for Sotera Health

Quarterly Income Statements for Sotera Health

Annual Cash Flow Statements for Sotera Health

Quarterly Cash Flow Statements for Sotera Health

Annual Balance Sheets for Sotera Health

Quarterly Balance Sheets for Sotera Health

Annual Metrics And Ratios for Sotera Health

Quarterly Metrics And Ratios for Sotera Health

Financials Breakdown Chart

Key Financial Trends

Sotera Health Financials - Frequently Asked Questions

When does Sotera Health's fiscal year end?

How has Sotera Health's net income changed over the last 6 years?

What is Sotera Health's operating income?

How has Sotera Health's revenue changed over the last 6 years?

How much debt does Sotera Health have?

How much cash does Sotera Health have?

How has Sotera Health's book value per share changed over the last 6 years?

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools